Top-News

Brainstorm Cell Therapeutics Aktie News

Aktie
WKN:  A40M9K ISIN:  US10501E3009 US-Symbol:  BCLI Land:  USA
0,63 $
+0,021 $
+3,45%
0,5407 € 15:43:26 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,88 Mio. €
Streubesitz
75,59%
KGV
-
Index-Zuordnung
-

Brainstorm Cell Therapeutics News

14.11.25 - PR Newswire
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
14.08.25 - PR Newswire
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
08.08.25 - PR Newswire
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update PR Newswire
17.07.25 - PR Newswire
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB PR Newswire
08.07.25 - PR Newswire
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness PR Newswire
16.06.25 - PR Newswire
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® PR Newswire
27.05.25 - PR Newswire
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials PR Newswire
19.05.25 - PR Newswire
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS PR Newswire
15.05.25 - PR Newswire
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
15.05.25 - PR Newswire
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-​Market Close Today and Sets Investor Call for Monday, May 19 PR Newswire
07.05.25 - PR Newswire
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 PR Newswire
06.05.25 - PR Newswire
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit PR Newswire
29.04.25 - PR Newswire
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting PR Newswire
10.04.25 - PR Newswire
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS PR Newswire
31.03.25 - PR Newswire
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update PR Newswire
26.03.25 - PR Newswire
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq PR Newswire
24.03.25 - PR Newswire
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update PR Newswire
30.12.24 - PR Newswire
BrainStorm Issues 2024 Letter to Shareholders
BrainStorm Issues 2024 Letter to Shareholders PR Newswire
09.12.24 - PR Newswire
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »